Macrocycles as factor xia inhibitors

A compound of Formula (I):

• or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein:
• ring A is phenyl;
• ring B is a 6-membered heteroaryl comprising:
• carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p;
• ring C is a 6-membered heteroaryl comprising:
• carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p;
• L1 is —CR5═CR5—;
• L is C3-8 alkylene;
• wherein said alkylene is substituted with 0-2 R7;
• Y is —CONH—;
• R1 is, independently at each occurrence, selected from the group consisting of:
• halogen, C1-6 alkyl, C1-4 alkoxy, C1-4 alkylthio, and C1-4 haloalkyl;
• R2 is independently a 5- to 7-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NH, N (C1-4 alkyl), O, and S(O)p, wherein said heterocycle is substituted with 0-2 R2a;
• R2a is, independently at each occurrence, selected from the group consisting of:
• halogen, C1-4 alkyl, —CH2OH, C1-4 alkoxy, OH, CF3, OCF3, CN, NH2, CO2H, CO2(C1-4 alkyl), COC1-4 alkyl, —CONH2, —CONH (C1-4 alkyl), —CON(C1-4 alkyl)2, —SO2(C1-4 alkyl), —SO2NH2, —SO2NH(C1-4 alkyl), and —SO2N(C1-4 alkyl)2;
• R3 is independently selected from the group consisting of:
• H, halogen, and CN;
• R4 is independently selected from the group consisting of:
• H, and C1-4 alkyl;
• R5 is, independently at each occurrence, selected from the group consisting of:
• H, halogen, OH, and C1-4 alkyl;
• R6 is, independently at each occurrence, selected from the group consisting of:
• halogen, C1-4 alkyl, CN, OH, and CF3;
• R7 is, independently at each occurrence, selected from the group consisting of:
• halogen, C1-4 haloalkyl, OCH2F, OCHF2, OCF3, and C1-4 alkoxy;
• and
• p is, independently at each occurrence, selected from the group consisting of:
• 0, 1, and 2.